NEW YORK (GenomeWeb) – Cancer Genetics reported after the close of the market on Monday that its second quarter revenues fell 6 percent year over year, principally due to a decrease in project-specific activities related to the timing of certain customers’ clinical studies and patient enrollment.

The firm also announced that it has entered into an agreement to acquire contract research organization vivoPharm for $12 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.